China-U.S. Tension Mars Biotech Giant BeiGene’s Shanghai Debut

BeiGene tumbled 16% in its mainland trading debut, after raising $3.5 billion and becoming the first company to be triple-listed in New York, Hong Kong and on Shanghai’s STAR Market.
( read original story …)

---